PureIMS Initiates Phase 1 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of Amikacin for Early Eradication Treatment of Tuberculosis

Month: July 2020

PureIMS Initiates Phase 1 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of Amikacin for Early Eradication Treatment of Tuberculosis

PureIMS Initiates Phase 1 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of Amikacin for Early Eradication Treatment of Tuberculosis

Delivery via inhaler could dramatically expand Amikacin’s clinical utility by immediate reduction of the contagiousness of Mycobacterium tuberculosis. Roden — July 1st, 2020 — PureIMS, a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory and systemic diseases, announces today the initiation of a Phase 1 clinical trial to evaluate the […]